HYPHEN BioMed was created in January 1999, by Dr. Jean Amiral and Ms. Anne Marie Vissac, researchers in applied biology with considerable industrial experience, in order to bring to medical and pharmaceutical research and hospital laboratories innovative tools for research and specialized biological diagnostics in thrombosis, hemostasis and auto immune diseases.

Founders’ Biography:


Jean Amiral is currently  Consultant and Senior Scientific Advisor.

He graduated for biochemistry (Lyon), Immunology (Creteil) and got a PhD (medical sciences blood vessels, Paris).
He founded HYPHEN BioMed in 1999 and was its president until end of 2012.  Before he was scientific director for Diagnostica Stago until 1998.
Jean Amiral has 40 years of experiences: in developing assay methods for hemostasis and thrombosis; designing new techniques for blood activation markers applied to cardio-vascular alterations and thrombotic tendencies, and developing assays for auto-immune diseases associated with an increased risk of thrombosis.
Some of his major accomplishments include the discovery of PF4 as the major target antigen for heparin induced antibodies (1992), and the pathogenic role of anti-protamine sulfate antibodies (2009).
He has authored/co-authored more than 200 articles, book chapters and patents.

Ms. Anne-Marie VISSAC

Ms. Anne-Marie Vissac founded HYPHEN BioMed in 1999 with Dr. Amiral and is the president of HYPHEN BioMed since end of 2012.

She is a biological chemistry engineer and has competence in coagulation, immunological technology and laboratory technical management. She had her educations in Clinical Chemistry MT (ENC Paris, France) and Biological Chemistry Engineer (SNIPF).
Her experiences include: Microbiology teacher (ENC, Paris, 1976); Biological Analysis Laboratory (Dr. SAMAMA and Dr. KERBOUL, Paris, 1977 to 1986); project leader in Research and Development of Immunological methods (Serbio, Stago group, Gennevilliers,
1986 to 1998); Technical Director of HYPHEN BioMed (Neuville-Sur-Oise, from 1998).
Her major accomplishments as a scientist include participation to the discovery of PF4 as the target antigen for Heparin Induced Antibodies in Jean Amiral’s research group.
She continues to give presentations at International congresses, and author or co-author of various papers actively.